UK Cancer Drugs Fund Adds Roche, Celgene Corporation And Exelixis, Inc. Drugs
Published: Mar 24, 2014
Three new drugs have been added to the Cancer Drugs Fund (CDF) in a move NHS England says could benefit 900 patients per year. The Fund will add new NHS coverage in England for Roche's Avastin (bevacizumab), Celgene's Abraxane (albumin bound paclitaxel) and Exelixis' Cometriq (cabozantinib). The CDF provides special funding for drugs that have clinical demand, but haven't been backed by England's cost effectiveness watchdog NICE, and in its first year saw particularly strong demand for Avastin.
Help employers find you! Check out all the jobs and post your resume.